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Abstract: 
 
 The Medicines for Malaria Venture (MMV) seeks to obtain an alternative cure for 
malaria that is simple to recreate, and of lower cost margin than the current drugs 
available. Over 50,000 fungal samples were investigated for anti-malarial properties, and 
those showing promise were further analyzed. The removal and purification of 
compounds from sample MSX232697 was performed using methanol extractions, liquid 
partitions, medium-pressure liquid chromatography (MPLC), and HPLC for compound 
isolation. Nuclear magnetic resonance (NMR), mass spectrometry (MS), and X-ray 
crystallography were used to characterize and elucidate compounds. The basic structures 
of the two compounds of interest are known to be delta-lactam derivatives. The final 
purified products will be submitted for bioassay and the results will determine whether 
the compounds will be viable for future drug development. 
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Introduction: 
 
 Malaria is an infectious disease caused by the parasite Plasmodium. This parasite, 
a eukaryotic protist, is transmitted via the bite of an infected mosquito. (Sutherland, 
2010) The type of mosquito that is responsible is the female anopheles mosquito. There 
are 5 different strains of the plasmodium parasite P.falciparum, P. vivax, P. ovale, P. 
malariae, and P. knowlesi. The most deadly stain is the p. falciparum causing the 
majority of the malarial deaths globally. (Snow, 2005) This disease is the fifth leading 
cause of death globally and the region of sub-Saharan Africa is the greatest affected. 
(Murray, 2012) The people that are most at risk of dying from malaria are young children, 
pregnant women, people with AIDS/HIV, and international travelers. (CDC, 2010)  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The map shows the prevalence rate of malarial cases in different regions of the 
world (WHO, 2004) 
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The symptoms for this disease are fever, shivering, joint pain, vomiting, anemia, jaundice, 
hemoglobinuria, retinal damage, and convulsions. (Beare, 2006) 
Transmission cycle of the parasite occurs when an Anopheles mosquito bites an  
infected human victim to obtain a blood meal. The mosquito contracts the Plasmodium 
sporozoites from the human’s blood and the parasite is carried in the salivary glands. The 
mosquito bites the next victim and sporozoites are released into the blood stream from the 
salivary glands. (Bledsoe, 2005) The parasite then develops in two phases, 
exoerythrocyticly and erythrocyticly. Initially, the parasite performs the exoerythrocytic 
phase and infects the liver cells. The parasites reproduce asexually within the cell 
between a period of 8 to 30 days. After this period the parasite has produced thousands of 
merozoites and are released into the blood stream once the liver cells are ruptured. 
(Bledsoe, 2005) The parasite then begins its erythrocytic phase and infects blood cells. 
Within the red blood cells the parasite multiplies asexually, bursting the red blood cell 
and moving toward the next one to infect. Over time some of the merozoites then turn 
into male and female gametocytes. When the mosquito intakes blood from an infected 
person, it will uptake both male and female gametocytes. (Bledsoe, 2005) This will allow 
the parasite to reproduce and sexually recombine its genes for more genetic diversity. The 
mosquito in this case is the carrier of the parasite and the human is the intermediate host. 
(Bledsoe, 2005) 
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Figure 2: The figure shows the life cycle of the Plasmodium parasite (NIAID, 2010) 
 
 
There are multiple treatments to combat the malaria parasite. Some of the more common 
drugs used are chloroquine, amodiaquine, quinine, mefloquine, halofantrine, atovaquone, 
artemisini, and its derivatives. (Delfino, 2002)  
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Figure 3: The figure shows the common anti-malarial drugs with the quinoline-
containing structures on the left and the artemisinin-type compounds on the right. 
(Delfino, 2002)  
 
These drugs can be taken orally or intravenously and the regimen given most commonly 
is artemisinin combination therapy. This type of treatment uses a combination of drugs to 
in increase the effectiveness against the parasite. (RSC, 2006) Many of the treatments 
require that you take the pills before you are potentially exposed to the parasite and up to 
4 weeks after the possible exposure date. This leads to excessive costs and makes these 
drugs inaccessible to the masses.  P. falciparum has also recently begun to become 
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resistant to certain treatments. The combination of high prices and parasite resistance has 
driven the research of anti-malarial drugs. (RSC, 2006) 
 Medicines for Malaria Venture (MMV) is a non-profit organization founded to 
discover, develop, and facilitate delivery of new as well as inexpensive anti-malarial 
drugs. (MMV, 2011) This organization has aided in funding many research institutions 
including the project that led to this thesis.  
 
 
Methods: 
 
The MMV project was the starting point for this thesis project. The sample 
selected for this thesis needed to show activity in the initial screening performed. The 
initial screening process used fungal samples provided by the company Mycosynthetix 
(MSX). Mycosynthetix provided over 50,000 samples for this research project to extract 
and test. The samples tested were all sent in 20 mL vials from the supplier, making 
extraction of the initial samples simple.  
The samples were first extracted using methanol. Methanol is used because it can 
dissolve a wide range of chemicals with varying polarity and it is easily evaporated.  
Once the sample sat in methanol for 24 hrs, the extract is then removed and plated on a 
96 well plate. This plate is then submitted to our collaborator that will perform bioassay 
and cytotoxicity tests on each crude extract. The bioassay test checks for inhibition of 
growth of f. plasmodium, the parasite which causes malaria. Cytotoxicity testing checks 
for inhibition of growth of human cells when exposed to crude extracts. The combination 
of high parasite growth inhibition and low cytotoxicity is the idea scenario for drug 
development. The results from these assays varied in each sample with some having 
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activity against the parasite and other showing no effect.  This initial screening test was 
performed to provide a qualitative test that would narrow down, which samples would be 
scaled up. 
The extracts that showed activity in the initial assay were then fractioned using 
medium pressure liquid chromatography (MPLC). The sample must first be prepared by 
combining silica gel with the crude extract. The initial methanol extract from the samples 
has to be dried down into a pre-weighed vial in order to determine the dry weight. The 
methanol and 3 times the crude’s mass of silica is used. Once the sample has been 
completely dissolved in the methanol, the silica and the re-dissolved extract are combined 
into a 250 mL round bottom flask. The round bottom flask is then place onto a rotary 
evaporator. This machine uses a vacuum, rotation, and a warm water bath to speed up the 
evaporation process. The sample was then placed on the machine with a glass catch 
containing cotton in between the round bottom flask and the condenser.  Once the sample 
is properly connected with safety clamps, the vacuum can then be started. The vacuum 
should initially be only a quarter pressure of the full vacuum. The next step is to lower 
the flask into the water bath, which should be at a lukewarm temperature. This low 
\temperature insures that no organic compound is degraded during the removal of 
methanol. Once the flask was in the water about half way, the rotation feature can be 
turned on to about 100 revolutions per minute. The vacuum can now be turned up quarter 
turns until one sees bubbling. This process should be very slow in order to prevent over 
flow of sample into the catch. The drying process should not take longer than 20 min. 
The sample should look like loose sand in the flask before removal. Once the sample is 
dry, the flask is then scrapped using a spatula to remove the silica that is stuck to the 
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walls of the flask. This sample is now ready to be packed into a sample column for the 
MPLC. Once the sample column is packed it can be attached to the machine and a normal 
phase separation column is used for this experiment.  The separation column size is based 
on the amount of crude extract used, so for this experiment a 4 gram flash column is 
necessary. Once the machine is properly set up a run must be formulated using three 
solvents. The solvents used in the run are hexane, ethyl acetate, and methanol. The 
experiment is 28 minutes in length. The initial starting concentration is 100 percent 
hexane for 2.5 minutes. At the point of 2.5 minutes to about 16.5 minutes is slow gradient 
increasing the second solvent concentration, ethyl acetate, to 100 percent.  Once the 
gradient is reaches 100 percent at 16.5 minutes, it is kept at this concentration till about 
21 minutes. Once the 21 minute mark is reached the third solvent, methanol is used. The 
gradient from 21 minutes to 28 minutes uses an increasing amount of methanol until no 
ethyl acetate is used at the end of the 28 minutes. This gradient is the standard for all 
samples that showed activity in the initial screening.  
The results from this fractionation technique were about 50 test tubes filled with 
solvent and a UV spectrum. The UV spectrum was then used to combine the test tubes in 
about 10 fractions to be submitted for assay. The fractions are transferred to 20 mL pre-
weighed vials and dried down to obtain a fraction weight. The fraction weight was used 
to determine how much DMSO is needed for the assays. The normal concentration of 
sample in each well should be about 2 mg of sample per 1 mL of DMSO. This will 
provide enough extract for our collaborators to perform a serial dilution on the extract 
and determine the samples that are of high interest. 
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The selection of my thesis sample was finally made after all these initial steps 
were taken on thousands of extracts. The sample that was chosen for my thesis was 
MSX232697. This sample showed primary interest on four MPLC fractions and 
secondary interest on another two fractions. Once the sample was selected a larger 3 liter 
scale up of MSX232697 was sent to the lab to be extracted. This scale up would provide 
enough sample mass for pure compounds to be extracted and identified.  The first step for 
the scale up is to extract the compounds using methanol. A methanol extraction is 
performed three times over three subsequent days. This will ensure the full extraction of 
the sample. The methanol was then dried down into the crude extract. A partition 
containing equal parts ethyl acetate and water was performed on the crude extract. The 
organic layer should be drawn off and ethyl acetate should be added twice more to ensure 
full extraction of organic compounds. The aqueous soluble materials are many times 
large and difficult to separate thus the partition makes the organic compound isolation 
much easier. The active compounds are in the organic layer of the partition. The ethyl 
acetate partition obtained was then dried down, weighed, and set up for MPLC 
fractionation using silica.  The same MPLC method used previously will be used for the 
ethyl acetate fraction. Using the UV spectrum the test tubes were separated into ten 
separate fractions from A to J. The fractions obtained were then dried down to obtain a 
weight. The fractions, the original crude, and the ethyl acetate partition were all then 
submitted for bioassay as well as cytotoxicity. The results from the testing showed to be 
consistent with the previous assay results with four primary hits and two secondary hits 
as shown in Figure 4. The next step in the purification process was to perform an HPLC 
on each fraction. Reverse phase LC was used with H2O and acetonitrile. Each of the 
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active fractions were re-dissolved with HPLC grade methanol and filtered into a 2 mL 
vial for injection. The experiments that were run and the UV detector was set to 
wavelength 225, 254, and 285nm. These wavelengths were selected because absorption at 
these wavelengths would indicate promising features in a compound such as double 
bonds and aromatic rings. The general HPLC method that was used started at 0% at 0 
minutes then the concentration increased to 40% ACN in 35 minutes. The concentration 
of ACN was then increased to 100% of the next 5 min to the 40 minute mark. Once at 
100% ACN the pumps were run until the 45 min mark.  Fraction E method differed 
slightly initial concentration of ACN starting at 10% and increasing to 25% in 40 minutes. 
After the 40 minute mark was reached the concentration of ACN would increase to 100% 
in the next 10 minutes. Once at 100% ACN, the gradient will run until 60 minutes was 
reached. 
These methods were run on both analytical and semi-prep columns. The method 
general method served as the basic method of separation for all the fractions. Fraction E 
had issues with the general method because the target peak would elute with smaller 
peaks making the separation difficult. The solution to this problem was to create the 
second method, making a slower gradient, which allowed for the target peak to be 
isolated with ease. The next step was to use the LCMS (liquid chromatography – mass 
spectrometry) to determine the purity and mass of the possible compounds collected. 
Once the mass was known, 800 MHz 1H NMR (Nuclear Magnetic resonance) was 
performed on each of the compounds. Deuterated methanol was used for all samples. The 
results showed impurities that further purification was needed. The peaks from fractions 
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E, H, and I were taken and combined into a single vial as shown in the flow chart. 
Combining the fraction into one vial would allow for purification in fewer injects.  
The HPLC General Method was used and provided sufficient separation for 
collect of the peaks. The second collection provided better peak purification and 
crystallization. During this collect two major peaks were isolated. NMR results of the 
purified compounds are shown in figures 10 and 11.  After the NMR data was collected, 
Q-TOF high-resolution mass spectrometry was used to generate a molecular formula. Q-
TOF uses a time measurement to determine an ion’s mass to charge ratio. The results 
displayed m/z=232.0974 for 3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihrdropyridin-
2(1H)-one and m/z=216.1045 for 3-(2-oxo-2-phenylethyl)-5,6-dihrdropyridin-2(1H)-one. 
Using the chemical formula determined by the Q-TOF, along with H-NMR data, and the 
chemical database AntiMarin, an initial structure was determined for peak 1 in fraction 
EHI. The second peak in fraction EHI also used the same determination process, but the 
structure could not be determined initially because there was no literature data available 
on the possible structure. In order to get an absolute structure for each peak, they were 
allowed to crystallize over the span of a week in order to obtain crystals. The crystals 
were then submitted for x-ray crystallography. The results showed two delta-lactam 
derivatives only differing by a single oxygen. The two compounds are 3-(2-(4-
hydroxyphenyl)-2-oxoethyl)-5,6-dihrdropyridin-2(1H)-one and 3-(2-oxo-2-phenylethyl)-
5,6-dihrdropyridin-2(1H)-one. The second compound, 3-(2-oxo-2-phenylethyl)-5,6-
dihrdropyridin-2(1H)-one, has no literature data and could possibly be a new compound. 
This compound has a possibility to be published in the future with more structural 
analysis. Once the compounds had been determined, they were submitted for bioassay 
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and cytotoxicity at 2 mg/mL. Both the compounds did not show activity at the nano-
molar range, making the compounds inactive against P.falciparum. 
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Results & Discussion 
 
MPLC Fractionation MSX232697 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C D E* F* G H* I* J 
1-6 7-10 11-12 13 14-17 18-19 20-25 26-31 32-34 35-42 
35.5 mg 355 mg 9.7 mg 4.7 mg 35.6 mg 25.1 mg 31.1 mg 21.6 mg 20.4 mg 71.3 mg 
 
Figure 4: The above shows the initial MPLC fraction for MSX232967. *The fractions 
are the primary fractions of interest. 
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A2
Run Length 28.0 Min
4x Column: 1
RediSep Column: Silica 12g  
Flow Rate: 30 ml/min
Equilibration Volume: 100.8 ml
Initial Waste: 0.0 ml
Air Purge: 0.5 min
Solvent: A1 hexane
Solvent: A2 methanol
Solvent: B1 ethyl acetate
Peak Tube Volume: Max.
Non-Peak Tube Volume: Max.
Loading Type: Solid
Wavelength 1 (red): 254nm
    Peak Width: 1 min
    Threshold: 0.20 AU
All Wavelength (orange): 200nm - 360nm
    Threshold: 0.20 AU
Run Notes: 
Duration %B Solvent A Solvent B
0.0 0.0 A1 hexane B1 ethyl acetate
2.1 0.0 A1 hexane B1 ethyl acetate
14.5 100.0 A1 hexane B1 ethyl acetate
4.2 100.0 A1 hexane B1 ethyl acetate
5.2 0.0 A2 methanol B1 ethyl acetate
2.1 0.0 A2 methanol B1 ethyl acetate
Peak # Start Tube End Tube
1 A:7 A:7
2 A:9 A:9
3 A:12 A:14
4 A:16 A:23
5 A:33 A:33
6 A:35 A:40
Sample: MMV-MSX-232697-ETOAC-0.8g Rf 200 Thursday 21 April 2011 12:12PM
Page 1 of 1
1 2 3 4 5
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1617181920
21 22 23 24 25
2627282930
31 32 33 34 35
3637383940
41 42 43 44 45
4647484950
51 52 53 54 55
5657585960
61 62 63 64 65
6667686970
Rack A
18 mm x 150 mm Tubes
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Initial MPLC Results 
 
Table 1: The red boxes indicate the fractions that were submitted for assay from my 
sample. The yellow highlighting indicates interest for the MMV project. The purple 
highlighting is of secondary interest not for the MMV project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   	   	   Rack	  #	  MMV	  Fractions	  CC	   	   	   	  
	   	   	   Concentration	  	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	   	  
A	  
MSX-­‐
239519	  
MSX-­‐
237697	  A	  
MSX-­‐
222068B	  
MSX-­‐
246535C	  
MSX-­‐
236693D	  
MSX-­‐
237539E	  
232697-­‐
H2O	  
232697	  
EtOAc	  F	  
NTOU-­‐
2578	  B	   CY-­‐4004	  D	  
MSX-­‐
298091D	  
MSX-­‐
245989	  
B	  
MSX-­‐
239519	  A	  
MSX-­‐
237697	  B	  
MSX-­‐
222068C	  
MSX-­‐
246535D	  
MSX-­‐
236693E	  
MSX-­‐
251810	  
232697	  
EtOAc	  
232697	  
EtOAc	  G	  
NTOU-­‐
2578	  C	   CY-­‐4004	  E	  
MSX-­‐
298091E	  
NTOU-­‐
2781	  A	  
C	  
MSX-­‐
239519	  B	  
MSX-­‐
237697	  C	  
MSX-­‐
222068D	  
MSX-­‐
246535E	  
MSX-­‐
237539	  
MSX-­‐
251810A	  
232697	  
EtOAc	  A	  
232697	  
EtOAc	  H	  
NTOU-­‐
2578	  D	  
MSX-­‐
237745	  E	  
MSX-­‐
245989A	  
NTOU-­‐
2781	  B	  
D	  
MSX-­‐
239519	  C	  
MSX-­‐
237697	  D	  
MSX-­‐
222068E	  
MSX-­‐
236693	  
MSX-­‐
237539A	  
MSX-­‐
251810B	  
232697	  
EtOAc	  B	  
232697	  
EtOAc	  I	   CY-­‐4004	  	  
MSX-­‐
298091	  
MSX-­‐
245989B	  
NTOU-­‐
2781	  C	  
E	  
MSX-­‐
239519	  D	  
MSX-­‐
237697	  E	  
MSX-­‐
246535	  
MSX-­‐
236693A	  
MSX-­‐
237539B	  
MSX-­‐
251810C	  
232697	  
EtOAc	  C	  
232697	  
EtOAc	  J	  
CY-­‐4004	  
A	  
MSX-­‐
298091A	  
MSX-­‐
245989C	  
NTOU-­‐
2781	  D	  
F	  
MSX-­‐
239519	  E	  
MSX-­‐
222068	  
MSX-­‐
246535A	  
MSX-­‐
236693B	  
MSX-­‐
237539C	  
MSX-­‐
251810D	  
232697	  
EtOAc	  D	  
NTOU-­‐
2578	  
CY-­‐4004	  
B	  
MSX-­‐
298091B	  
MSX-­‐
245989D	  
NTOU-­‐
2781	  	  
G	  
MSX-­‐
237697	  
MSX-­‐
222068	  A	  
MSX-­‐
246535B	  
MSX-­‐
236693C	  
MSX-­‐
237539D	  
MSX-­‐
251810E	  
232697	  
EtOAc	  E	  
NTOU-­‐
2578A	  
CY-­‐4004	  
C	  
MSX-­‐
298091C	  
MSX-­‐
245989E	   DMSO	  
H	   	  	   	  	   	  	   	  	   P	   P	   P	   P	   N	   N	   N	   N	  
	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	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Figure 5: The arrow indicates peak 1 that was collected from MPLC Fraction E by 
HPLC purification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:  The arrows indicate the peaks collected from MPLC Fraction F by HPLC 
purification. 
Peak 1 Fraction E 
Peak 1 Peak 2 
Peak 3 
Peak 4 
Fraction F 
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Figure 7: The arrows indicate the peaks collected from MPLC Fraction H by HPLC 
purification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: The arrow indicates the peak of collected from MPLC Fraction I by HPLC  
purification. 
 
 
 
Peak	  1	   Peak	  2	   Fraction H 
Peak	  1	   Fraction I 
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Figure 9: The arrows indicate the fractions collected from Fraction EHI by HPLC 
purification. The EHI fraction is all the peaks from fractions E, H, and I combined. The 
black line represents 225 nm, the pink line represents 254 nm, and the blue line 
represents 285 nm wavelength.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak	  1	  
Peak	  2	  
Fraction EHI 
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MSX 232697 
EtOAc Partition 
800 mg.  
Fraction 
A 
35.5 mg  
Fraction 
B 
355 mg 
Fraction 
C 
9.7 mg 
Fraction 
D 
4.7 mg  
Fraction 
E  
35.6 mg 
Fraction E 
Peak 1 
1.69 mg 
Fraction 
F 
25.1 mg 
Fraction 
G 
31.1 mg 
Fraction 
H  
21.6 mg 
Fraction H  
Peak 1  
0.4 mg 
Fraction H 
 Peak 2 
0.3 mg 
Fraction 
I  
20.4 mg 
Fraction I 
Peak 1 
1.47 mg 
Combination  
fraction EHI 
3.73 mg 
EHI  
Peak 1 
1.3 mg 
EHI  
Peak 2 
0.2 mg 
Fraction 
J 
71.3 mg 
HO
O
N
O
H
3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihydropyridin-2(1H)-one
O
N
O
H
3-(2-oxo-2-phenylethyl)-5,6-dihydropyridin-2(1H)-one
HO
O
N
O
H
3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihydropyridin-2(1H)-one
O
N
O
H
3-(2-oxo-2-phenylethyl)-5,6-dihydropyridin-2(1H)-one
MPLC Fractionation 
Solvents used Hexane, Ethyl Acetate 
and Methanol. 
 
MSX 232697 and the fractions in 
red showed inhibition against the 
parasite 
 
HPLC Fractionation 
Solvents used Acetonitrile and Water 
 
HPLC Repurification 
Same solvents used as before and all the 
peaks collected were combined into one 
fraction in order to reduce amount of 
purification runs. 
 
Pure Compounds  
 
 
Flow	  Chart:	  Fractionation	  Scheme	  of	  MSX232697	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Figure 10: H-NMR spectrum on 800 MHz of 3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-
dihrdropyridin-2(1H)-one (Peak 1) using Dueterated Methanol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: H-NMR spectrum on 800 MHz of 3-(2-oxo-2-phenylethyl)-5,6-
dihrdropyridin-2(1H)-one (Peak 2) using Dueterated Methanol.   
HO
O
NH
O
O
NH
O
HO
O
NH
O
O
NH
O
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   EHI	  Peak	  1	  
Lit.	  
spectrum	   Difference	  
Doublet	   6.82	   6.88	   -­‐0.06	  
Doublet	   7.9	   7.96	   -­‐0.06	  
Triplet	   6.56	   6.56	   0	  
Multiplet	   2.4	   2.44	   -­‐0.04	  
Triplet	   3.41	   3.46	   -­‐0.05	  
Broad	  
Sing.	   3.89	   3.93	   -­‐0.04	  
 
Table 2: This table compares literature H-NMR spectrum with the spectrum obtained for 
pure compound 3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihrdropyridin-2(1H)-one (Peak 
1)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: High resolution mass spectrum of 3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-
dihrdropyridin-2(1H)-one (Peak 1) using a Q-TOF. This figure shows the compound plus 
a proton (m/z = 232.0974) and also the compound plus a sodium adduct (m/z = 254.0793)  
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Figure 13: High resolution mass spectrum of 3-(2-oxo-2-phenylethyl)-5,6-
dihrdropyridin-2(1H)-one (Peak 2) using Moffitt’s Agilent 6550 iFunnel Q-TOF 
LC/MS . This figure shows the compound plus a proton and the compound plus 
two protons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Crystal structure conformation of 3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-
dihrdropyridin-2(1H)-one (Peak 1) using x-ray crystallography. 
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Figure 15: Crystal structure conformation of 3-(2-oxo-2-phenylethyl)-5,6-
dihrdropyridin-2(1H)-one (Peak 2) using x-ray crystallography. 
 
 
Pure compound Bioassay Results: The concentration of the samples submitted was 2 
mg/mL and a serial dilution was performed. Both compounds did not show activity at the 
nano molar range and thus ruling out these compounds for anti-malarial drug 
development.  
 
Conclusion:  
  
 The two compounds identified in this thesis did not show promising anti-malarial 
properties thus ruling them out for further development of anti-malarial drugs. Compound 
3-(2-(4-hydroxyphenyl)-2-oxoethyl)-5,6-dihrdropyridin-2(1H)-one (Peak 1) has been  
discovered in two different organisms the fungus, H. grisea var thermoidea,  and the 
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sponge, H. melanodocia.(Andrioli, 2012) The literature shows that this compound has 
anti-allergic properties. Compound 3-(2-oxo-2-phenylethyl)-5,6-dihrdropyridin-2(1H)-
one (Peak 2) being a unreported in Scifinder and Marin Lit. This newly identified 
compound could possess these similar anti-allergic properties because of structural 
similarities. This type of research could be conducted in the future along with other 
assays to find an application for this novel compound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   26	  
References 
 
1. Beare NA, Taylor TE, Harding SP, Lewallen S, Molyneux ME 
(November 1, 2006). "Malarial retinopathy: a newly established diagnostic sign in 
severe malaria". Am. J. Trop. Med. Hyg. 75 (5): 790–7. PMC 2367432. 
PMID 17123967 
2. Bledsoe GH (December 2005). "Malaria primer for clinicians in the United States".  
South. Med. J. 98 (12): 1197–204; quiz 1205, 1230. 
doi:10.1097/01.smj.0000189904.50838.eb. PMID 16440920. 
3. Centers for Disease Control and Prevention (2010, Febr 08). Center for disease 
 control:about malaria. Retrieved from  
http://www.cdc.gov/malaria/about/facts.html 
4.Christopher JL Murray, Lisa C Rosenfeld, Stephen S Lim, Kathryn G Andrews, Kyle J  
Foreman, Diana Haring, Nancy Fullman, Mohsen Naghavi, Rafael Lozano, Alan 
D Lopez. "Global malaria mortality between 1980 and 2010: a systematic 
analysis". The Lancet, Volume 379, Issue 9814, Pages 413 - 431, 4 February 2012 
5. DELFINO, Reinaldo T.; SANTOS-FILHO, Osvaldo A.  and  FIGUEROA-VILLAR,
 José D.. Type 2 antifolates in the chemotherapy of falciparum malaria. J. Braz. 
Chem. Soc. [online]. 2002, vol.13, n.6, pp. 727-741. ISSN 0103-5053 
6.  Medicines for malaria venture. (2011). Retrieved from 
http://www.mmv.org/about-us/malaria-and-medicines 
7. NIAID. (2010, March 22). National institute of allergy and infectious disease.  
Retrieved from http://www.niaid.nih.gov/topics/malaria/pages/lifecycle.aspx 
	   27	  
8. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005). “The global distribution
 of clinical episodes of Plasmodium falciparum malaria.” Nature 434 (7030):  
214–7 
9. Stephens, W. E., A Pulsed Mass Spectrometer with Time Dispersion Phys. Rev., 1946, 
69, 691 
10. Sutherland CJ, Tanomsing N, Nolder D, et al. (May 2010). “Two Nonrecombining
 Sympatric Forms of the Human Malaria Parasite Plasmodium ovale Occur
 Globally” J. Infect. Dis. 201 (10): 1544–50. 
11. Royal Society of Chemistry. July 2006 “Artemisinin and a New Generation of
 Antimalarial Drugs." Web. 20 Apr. 2012.
 <http://www.rsc.org/Education/EiC/issues/2006July/Artemisinin.asp>. 
12. W.J. Andrioli, M.S. Santos, V.B. Silva, R.B. Oliveira, D.A. Chagas-Paula, J.A. Jorge,  
N.A.J.C. Furtado, M.T. Pupo, C.H.T.P. Silva, R.M.Z.G. Naal, J.K. Bastos “D-
Lactam derivative from thermophilic soil fungus exhibits in vitro anti-allergic 
activity” Natural Product Research 2012, 1-8  
13. World health organization. (2011) Retrieved from
 http://www.who.int/mediacentre/factsheets/fs094/en/index.htmL 
14.Yalamanchili Gopichand, Francis J. Schmitz  J. “Two novel lactams from the marine  
sponge Halichondria melanodocia” Org. Chem., 1979, 44 (26), pp 4995–4997  
 
 
 
 
